Navigation Links
Circulating tumor cells in blood can predict a patient's response to chemotherapy

Scientists from Granada have demonstrated, for the first time, that detecting circulating tumour cells (CTCs) in blood and studying the presence of certain genetic markers in them is a technique that allows specialists to predict, with great precision, the response that advanced-cancer patients will have to chemotherapy, as well as the associated secondary effects they may suffer. The key lies in identifying specific proteins in these cells, which make them particularly sensitive to specific drugs.

The scientists, from the Circulating Tumour Cells and Metastasis research group of GENYO (Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Govt.) have received an award at the 9th International Symposium on Minimal Residual Cancer, held recently in Paris, for their study into the use of CTCs and specific markers in these cells, as a clinical tool to determine the response to treatments administered to patients with advanced cancer of the colon.

The patients, studied in the Oncology Unit of the Clinical Hospital of Granada and the Hospital of Motril, underwent a standard treatment in this illness, which includes chemotherapy and a specific monoclonal antibody that reduces the vascularization of the tumour. The study was carried out in collaboration with the Roche Farma laboratory.

The importance of CTCs as the origin of metastasis, which, in turn, is the cause of more than 9 out of every 10 deaths from cancer, has been the subject of work by this group in GENYO for over four years, lead by the University of Granada professors, Jos Antonio Lorente, Mara Jos Serrano and Jos Luis Garca Puche.

GENYO co-operates actively with other Spanish hospitals such as Jan (Dr. Snchez Rovira's team), Crdoba (Dr. Aranda's team) or Almera - Torrecrdenas (with Dr. Juan Torres), as well as carrying out other particularly relevant collaborations with the Dexeus Institute or the Hospital del Mar in Barcelona, along with others in Granada (teams led by Drs. Expsito, Delgado, Czar and Cueto, among others).

Eight Studies

This test on CTCs is one of eight studies the Granada research group is currently carrying out on patients affected by various particularly relevant pathologies in oncology, such as breast cancer, lung cancer, peritoneal carcinomatosis or prostate cancer. These studies have been funded by the Andalusian Regional Government's Health Council, the University of Granada and the pharmaceutical sector.

Due to the importance of this research in applying anti-cancer treatments with greater precision and with fewer side-effects, as well as the importance of CTCs in diagnosing the illness, the work of this GENYO group has caught the attention of the pharmaceutical industry, which habitually collaborates in the carrying out of some of the studies, such as SANOFI, Pangaea, Janssen, Amgen, Ingeniatrix or Roche Farma.


Contact: José Antonio Lorente
University of Granada

Related medicine news :

1. New research finds flu shot effective regardless of circulating flu strain
2. Sous Vide Circulating Bath Systems Enable Chefs to Achieve Perfect Results
3. Detecting circulating tumor cells
4. New technology allows scientists to capture and preserve cancer cells circulating in the bloodstream
5. Capturing circulating cancer cells could provide insights into how disease spreads
6. Blocking antioxidants in cancer cells reduces tumor growth in mice
7. Why tumors become resistant to chemotherapy?
8. New immunotherapy for malignant brain tumors
9. Study Funded by National Foundation for Cancer Research Reveals Imaging Studies May Predict Tumor Response to Anti-Angiogenic Drugs
10. American Brain Tumor Association-Funded Research Spurs Development of New Treatments
11. Study unveils SINEs potential of re-activating tumor fighting proteins within a cell
Post Your Comments:
Related Image:
Circulating tumor cells in blood can predict a patient's response to chemotherapy
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from reveals that behind the tendency to set ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... develops, markets and sells medical devices and wearable sleep ... a strategic cooperation agreement with Hongyuan Supply Chain Management ... on June 20, 2016, to develop Dehaier,s new Internet ... agreement, Dehaier will leverage Hongyuan Supply Chain,s sales platform ...
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
Breaking Medicine Technology: